- Home
- ANTA vs PLX Comparison
ANTA vs PLX Comparison
Compare ANTA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | PLX |
|---|---|---|
| Founded | 2022 | 1993 |
| Country | Singapore | United States |
| Employees | 113 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.1M | 168.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ANTA | PLX |
|---|---|---|
| Price | $6.65 | $2.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.17 | $12.00 |
| AVG Volume (30 Days) | 1.8K | ★ 626.2K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | $21.95 | $36.81 |
| Revenue Next Year | $30.46 | N/A |
| P/E Ratio | $19.77 | ★ $9.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $1.34 |
| 52 Week High | $13.82 | $3.19 |
Technical Indicators
Market Signals| Indicator | ANTA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 54.72 |
| Support Level | $6.80 | $2.03 |
| Resistance Level | $9.81 | $2.17 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 23.64 | 62.50 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.